Session: How Can We Manage High-Risk Hematologic Malignancies in the Community?
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, Diversity, Equity, and Inclusion (DEI) , Study Population, Human
Disclosures: Birhiray: Pharmacyclics: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; PUMA BIOTECHNOLOGY: Consultancy, Honoraria, Speakers Bureau; LILLY: Consultancy, Honoraria, Speakers Bureau; NORVATIS: Consultancy; INCYTE: Consultancy, Honoraria, Speakers Bureau; SANOFI?GENZYME: Consultancy, Honoraria, Speakers Bureau; DOVA: Honoraria, Speakers Bureau; EXELIXIS: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; ABBVIE: Consultancy, Honoraria, Speakers Bureau; ASTRAZENECA: Consultancy, Honoraria, Speakers Bureau; BAYER: Consultancy, Honoraria, Speakers Bureau; ARRAY BIOPHARMA: Consultancy, Honoraria; GENENTECH: Consultancy, Honoraria; TAKEDA: Consultancy, Honoraria, Research Funding; DIACHII SANCHO: Consultancy, Honoraria, Research Funding; MORPHOSYS: Consultancy, Honoraria, Speakers Bureau; REGENERON: Consultancy, Honoraria, Research Funding, Speakers Bureau; KITE: Consultancy, Honoraria; GILEAD: Consultancy, Honoraria; IPSEN: Consultancy, Honoraria; STEMLINE: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; Genmab: Consultancy; CARIS: Consultancy, Honoraria; SERVIER: Honoraria, Speakers Bureau; AMGEN: Consultancy, Honoraria, Speakers Bureau; TerSera: Consultancy, Honoraria; Coherus: Consultancy, Honoraria, Speakers Bureau.
OffLabel Disclosure: Discussing clinical research in community practice
See more of: Education Program